Search
Welcome
  • Login
  • Register
Forgot Password?
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
Not a subscriber? Subscribe here
Register Now
  • Login
  • Register
Forgot Password?
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
                       
Careers & Tenders
Newsletters
Subscribe
The Mail & Guardian
      SUBSCRIBE / Support independent journalism                   CAREERS & TENDERS / Visit careers.mg.co.za                   WHATSAPP? / Follow the M&G WhatsApp channel here            
Login / Register

LOGIN

  • News
    • Africa
    • Business
    • Editorial
    • Education
    • Health
    • Motoring
    • National
    • Sci-tech
    • Sport
    • World
  • Thought Leader
  • Politics
  • Green Guardian
  • Friday
  • Features
    • Buthelezi, the King’s Hand
    • Cabinet Report Cards 2023
    • Cabinet Report Cards 2012-2021
    • The Fiscal Cliff
  • Research World
    • Submissions
    • Papers
  • 200 Young South Africans
  • Events
    • 200 Young South Africans
    • Greening The Future
    • Power Of Women
      • 2024 Edition
    • Critical Thinking Forum
    • Youth Summit
    • Webinars
  • More..
    • Partners
    • Podcasts
    • Crossword
    • Digital Editions
    • Register
    • WhatsApp Channel
    • Login
    • Lost Password

           

lenacapavir

The US’s NIH funds R6.65 billion of research in South Africa
Health
/ 30 April 2025

The US’s NIH funds R6.65 billion of research in South Africa

If all of its National Institutes of Health funding falls away, the country could lose 70% of its medical research capacity

By Linda Pretorius and Jacques Verryn
The six-monthly anti-HIV jab could end Aids in SA by 2032
Health
/ 9 April 2025

The six-monthly anti-HIV jab could end Aids in SA by 2032

A modelling study released in March gives a clue at which price the jab, lenacapavir, would be worth the health department’s while

By Mia Malan
The Global Fund will roll out the twice-yearly anti-HIV jab — with or without Pepfar
Health
/ 5 March 2025

The Global Fund will roll out the twice-yearly anti-HIV jab — with or without Pepfar

In December, the Global Fund and the US President’s Emergency Plan for Aids Relief committed to funding the roll-out of lenacapavir in countries they support

By Ida Jooste
Too little, too late: What a Pepfar waiver can’t do for HIV
Health
/ 3 February 2025

Too little, too late: What a Pepfar waiver can’t do for HIV

The US has said who qualifies for a waiver during the Trump administration’s pause in foreign aid but it doesn’t allow for anti-HIV pills, unless for pregnant women

By Mia Malan
What it would it take to get the 6-monthly anti-HIV jab to South Africa
Health
/ 31 July 2024

What it would it take to get the 6-monthly anti-HIV jab to South Africa

Lenacapavir drug can be made for as little as R740 per year for each patient

By Mia Malan and Linda Pretorius
South Africa to roll out HIV prevention injection CAB-LA in clinics, with US donation
Health
/ 22 July 2024

South Africa to roll out HIV prevention injection CAB-LA in clinics, with US donation

CAB-LA virtually eliminates someone’s chances of contracting HIV, but costs about four times more than the government can afford to pay

By Mia Malan and Linda Pretorius

MAIL & GUARDIAN

ABOUT

About
Contact
Advertise

SUBSCRIPTIONS

Subscribe
Newsletters

FOLLOW

WhatsApp Channel
Twitter
Facebook
YouTube
Instagram
LinkedIn
TikTok
Threads

FLAGSHIP EVENTS

200 Young South Africans
Power Of Women
Greening The Future

LEGAL & CORRECTIONS

Privacy Policy
Cookie Policy
Ethics & Social Media Policy

RESOURCES

Mail & Guardian Careers
Property for sale


Mail & Guardian

© 2025 The Mail & Guardian. All rights reserved.

  • Login
  • Register
Forgot Password?
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
body::-webkit-scrollbar { width: 7px; } body::-webkit-scrollbar-track { border-radius: 10px; background: #f0f0f0; } body::-webkit-scrollbar-thumb { border-radius: 50px; background: #dfdbdb }